Related by context. All words. (Click for frequent words.) 74 Inhibitors 73 Receptor Antagonist 73 Kinase Inhibitor 72 Receptor Agonist 70 Receptor Antagonists 69 selective inhibitor 69 Inhibits 69 inhibitor 68 HDAC Inhibitor 68 Anti Tumor Activity 68 Protease Inhibitor 68 Tumor Necrosis Factor 68 Drug Candidate 68 Small Molecule 68 Chemokine Receptor 68 Orally Active 68 Novel Mechanism 68 Transcription Factor 68 Epidermal Growth Factor Receptor 68 Combination Therapy 67 selective antagonist 67 Hsp# Inhibitor 67 selectively inhibits 67 Monoclonal Antibody 67 Anti Tumor 67 small molecule inhibitor 66 kinase inhibitor 66 sodium glucose cotransporter 66 Present Preclinical Data 66 phosphatidylinositol 3 66 Antitumor 66 Factor Receptor 66 Prodrug 66 Recombinant Human 66 Potent Inhibitor 66 Prolongs Survival 66 Inhibition 65 Attenuates 65 Liposomal 65 investigational humanized monoclonal antibody 65 Kinase Inhibitors 65 Well Tolerated 65 Signaling Pathway 65 highly selective inhibitor 65 Aurora Kinase 65 antisense oligonucleotide 65 reversible inhibitor 65 Tyrosine Kinase Inhibitor 65 Kinase 65 Antagonist 65 hypoxia inducible factor 64 Phosphorylation 64 Novel Oral 64 potently inhibit 64 Denufosol 64 Cytochrome P# 64 polymerase inhibitor 64 PKC# 64 Enzastaurin 64 DNA intercalator 64 Receives Orphan Drug Designation 64 Janus Kinase 64 Bosutinib 64 HCV protease 64 selective inhibition 64 potent inhibitor 64 Histone 64 Induces 64 antisense inhibitor 64 Protein Kinase 64 Diabetic Nephropathy 63 Tubulin 63 Protease 63 Oligonucleotide 63 immunostimulatory 63 Selective Inhibitor 63 receptor antagonist 63 orally bioavailable 63 Proteasome 63 induces apoptosis 63 AnaSpec Introduces 63 Androgen Receptor 63 histone deacetylase HDAC inhibitor 63 selective agonist 63 Analogs 63 Phase IIa Clinical Trial 63 Interferon gamma 63 Mouse Model 63 Histone Deacetylase 63 receptor antagonists 63 HDACi 63 Phase IIb Clinical Trial 63 Aptamer 63 Reductase 63 Protein Kinase C 63 Nucleoside 63 Systemic Delivery 62 PEGylated Fab fragment 62 poly ADP ribose polymerase 62 Macrophage 62 Diabetic Neuropathy 62 Bevacizumab 62 Angiogenic 62 receptor tyrosine kinase inhibitor 62 Allosteric 62 Monotherapy 62 CCR2 62 Novel Inhibitor 62 Janus kinase 62 Antitumor Activity 62 selective adhesion molecule 62 Tumor Targeting 62 Kinases 62 liposomal formulation 62 Pathway Inhibitor 62 P2Y 62 nucleoside analog 62 VEGF receptor 62 humanized anti 62 Catenin 62 oral prodrug 62 Voreloxin 62 tyrosine kinase receptor 62 Parathyroid Hormone 62 Sustained Release 62 Bruton tyrosine kinase 62 p# mitogen activated 62 Irinotecan 62 Angiotensin Converting Enzyme 62 HDAC 62 vascular disrupting agent 62 Clinical Trial Results 62 inhibitors 62 Platelet Derived Growth 62 Estrogen Receptor 62 cyclin dependent kinase inhibitor 62 Calcineurin 62 Previously Treated 62 Cyclooxygenase 62 Myeloid 62 humanized monoclonal 62 Phase 2b Trial 62 Perifosine 62 Cyclophosphamide 62 Dose Response 62 PDE4 inhibitor 62 Pharmacokinetics PK 62 Dasatinib 62 Single Dose 62 receptor tyrosine kinase 62 Mucosal 62 cystic fibrosis transmembrane conductance 62 Phase III Clinical Trial 61 Interferon Alpha 61 MEK inhibitor 61 II Clinical Trial 61 histone deacetylase 61 mTOR mammalian target 61 phosphorylates 61 histone deacetylase inhibitor 61 RNAi Therapeutic 61 Erlotinib 61 Tyrosine Kinase 61 Neuroprotective 61 Anti Angiogenic 61 Bortezomib 61 erlotinib Tarceva ® 61 downregulates 61 Treatment Regimen 61 Oral Fingolimod 61 Study Evaluating 61 Tolerability 61 Cyclooxygenase 2 61 Tumor Suppressor 61 Oral Formulation 61 Interferon Gamma 61 Factor VEGF 61 matrix metalloproteases 61 Inhibiting 61 Angiotensin II 61 pan HDAC inhibitor 61 CCR1 61 Is Well Tolerated 61 Polymorphisms 61 HDAC inhibitor 61 small molecule inhibitors 61 Neuroprotection 61 Pulmonary Arterial Hypertension 61 Therapeutic Efficacy 61 Blinatumomab 61 Ligands 61 Meets Primary Endpoint 61 Maribavir 61 Epothilone 61 Nucleotide 61 HDAC enzymes 61 antiproliferative activity 61 Preclinical studies suggest 61 Antiangiogenic 61 Upregulation 61 humanized monoclonal antibody 61 antiapoptotic 61 Adenosine 61 Synthase 61 extracellular signal 61 Glucocorticoid 61 Vascular Endothelial Growth 61 Agonist 61 Modulates 61 Isavuconazole 61 peptide CGRP 61 Epithelial 61 thrombin receptor 61 Secretion 61 PI3 Kinase 61 SensoLyte ® 61 Phase 2b Clinical Trial 61 immunomodulatory 61 PNP inhibitor 61 mitogen activated protein kinase 61 Therapeutic Potential 61 MEK1 61 Dose Escalation Study 61 Granulocyte Colony Stimulating Factor 61 MEK ERK 61 selective kinase inhibitor 61 Angiotensin 61 Polymerase 60 chemokine receptor 60 Peginterferon 60 Cell Adhesion 60 potent inhibition 60 sphingosine 1 60 Transgenic Mice 60 Antisense Oligonucleotides 60 N methyl 60 CK2 60 PI3K/mTOR 60 Anti Inflammatory 60 Targeted Therapy 60 insulin sensitizers 60 Oligonucleotides 60 monocyte chemotactic protein 60 Lenalidomide 60 Pharmacodynamics 60 Pemetrexed 60 receptor partial agonist 60 peroxisome proliferator activated 60 enzyme inhibitor 60 PTP 1B 60 Patients Treated 60 Protease Inhibitors 60 Rituximab 60 type glutamate receptor 60 TNF Alpha 60 LPA1 receptor 60 Dehydrogenase 60 protein tyrosine phosphatase 1B 60 Oncogenic 60 Inflammatory Arthritis 60 interferon IFN 60 EGFR HER2 60 Chronic Hepatitis C 60 Replacement Therapy 60 Hypercholesterolemia 60 CDK inhibitor 60 Fc fusion protein 60 Potent Anti 60 Dapagliflozin 60 Initiates Clinical 60 Calcitonin 60 Smooth Muscle 60 mediated apoptosis 60 Flt3 60 Novel Small Molecule 60 SGLT2 60 Newly Diagnosed 60 Adjuvant Therapy 60 phosphoinositide 3 60 Dose Ranging Study 60 Cytotoxic 60 Suppresses 60 Dendritic Cells 60 NS5A 60 ADP receptor antagonist 60 cyclin dependent kinases 60 orally administered inhibitor 60 peripherally acting 60 Leukotriene 60 Squalamine 60 Secretory 60 Akt activation 60 Relapsed Refractory 60 Advanced Renal Cell 60 selective phosphodiesterase 60 signal transduction inhibitor 60 Placebo Controlled Trial 60 SIRT2 60 Clinical Trial Evaluating 60 Secretase 60 Capecitabine 60 histone deacetylase inhibitors 60 BAL# [001] 60 ErbB 60 receptor subtype 60 Assay Kit 60 Transcriptional 60 LPA1 60 anti angiogenic agent 60 antagonist LAMA 59 PDGFR 59 Cancer Cells 59 targeted antifolate 59 multikinase inhibitor 59 proteasome inhibitors 59 MTP inhibitor 59 FasL 59 ubiquitin ligase 59 Factor NGF 59 Retinoic Acid 59 anti CD3 59 Controlled Trial 59 Binding Protein 59 Taxane 59 receptor agonists 59 Peptide 59 Methylnaltrexone 59 Low Dose 59 imatinib Gleevec ® 59 JAK1 59 Doxorubicin 59 deacetylase 59 induced apoptosis 59 Antagonists 59 Nerve Growth 59 Amino Acid 59 Fibrinogen 59 Cytarabine 59 MET VEGFR2 59 AKT inhibitor 59 Tumor necrosis factor 59 P#X# 59 PEGylated anti 59 reversible inhibitors 59 irreversible inhibitor 59 Vorinostat 59 substrates inhibitors 59 CYP#A# CYP#D# 59 chimeric monoclonal antibody 59 Antisense 59 CTLA 4 59 long acting muscarinic 59 NMDA antagonist 59 Induces Apoptosis 59 pathophysiological effects 59 Anticancer Agent 59 murine model 59 Interferon alpha 59 Factor VIIa 59 novel topoisomerase 59 Fibroblast Growth Factor 59 AT1R 59 Microtubule 59 PI3 kinase 59 ERK signaling 59 MEK inhibitors 59 Receptor 59 P#Y# [002] 59 receptor agonist 59 alkylating agent 59 mineralocorticoid receptor 59 ERK1 2 59 dopamine reuptake 59 Pegylated 59 IAP inhibitor 59 Cytotoxicity 59 activin receptor type 59 Receptor Agonists 59 acetylcholinesterase 59 Files IND 59 Assay Kits 59 Decitabine 59 Autologous Stem Cell Transplantation 59 Monoclonal 59 Phase 2b Study 59 fosbretabulin 59 PDGF receptor 59 Vidofludimus 59 Pralatrexate 59 Tyrosine Kinase Inhibitors 59 metabotropic glutamate receptor 59 Prodrugs 59 topoisomerase II inhibitor 59 5HT 59 dipeptidyl peptidase IV 59 anticancer agent 59 Orally administered 59 Progenitor Cells 59 Intracellular 59 Myelodysplastic Syndromes 59 molecule epidermal 59 dopamine D2 59 Universal Flu Vaccine 59 enzyme inhibitors 59 cytoprotective 59 Inhalation Aerosol 59 vWF 59 Antibody 59 anti angiogenic 59 nucleoside analogues 59 Patent Covering 59 Patients Treated With 59 intravenously administered 59 Phase IIa Trial 59 Placebo Controlled Study 59 adhesion molecule 59 glycogen synthase kinase 59 GW# [003] 59 methionine aminopeptidase 59 VEGFR2 59 opioid receptor antagonist 59 Randomized Double Blind Placebo 59 Vascular Inflammation 59 c MET 59 T#M 59 gamma secretase inhibitor 59 Gene Mutation 59 5 HT6 receptor 59 ischemia reperfusion injury 59 Hepatitis C Genotype 59 Anthracycline 59 TNF Tumor Necrosis Factor 59 PI3K inhibitor 59 Complicated Skin 58 selectively inhibit 58 P2X 58 cortisol synthesis 58 downregulation 58 S#P# 58 Muscarinic 58 Apoptosis 58 transient receptor 58 BMP2 58 angiotensin receptor 58 Cannabinoid 58 Oxidative 58 Phase III Trial 58 mu opioid receptor antagonist 58 Syk 58 Cathepsin S 58 pro apoptotic 58 Inactivation 58 p# alpha [001] 58 Myelofibrosis 58 Glycosylation 58 Transdermal Delivery 58 selective inhibitors 58 receptor antagonism 58 Epidermal Growth Factor 58 Phosphodiesterase 58 small molecule tyrosine 58 selective modulator 58 Imatinib 58 annexin V 58 Talabostat 58 Therapeutic Antibody 58 Benign Prostatic Hyperplasia 58 TGF Beta 58 Novel Compound 58 proteasome inhibitor 58 calcitonin gene related 58 Long Term Efficacy 58 2 methoxyestradiol 58 regulated kinase 58 Immune Responses 58 novel histone deacetylase 58 Mesalamine 58 Neuroprotective Effects 58 Skeletal Muscle 58 Multidrug Resistance 58 muscarinic antagonist 58 angiotensin receptor blocker ARB 58 Treating Chronic 58 Interferon alfa 58 Integrase 58 Efficacy Trial 58 Pertuzumab 58 Protein kinase 58 Transmembrane 58 CD# CD# 58 Oral Mucositis 58 Glucagon Like Peptide 58 JAK2 enzyme 58 Metastatic Colorectal Cancer 58 Clinical Outcome 58 TMC# [002] 58 5 HT2A inverse 58 BMS # 58 immunomodulator 58 CCR5 antagonist 58 2 inhibitor CYT# 58 Inhaled Corticosteroids 58 Shows Promise Against 58 #HT#A 58 ALN TTR 58 Nedd4 58 HDAC inhibitors 58 tyrosine kinase 58 AEG# 58 Mimetics 58 Anti Inflammatory Drugs 58 Linaclotide 58 PSN# [002] 58 Fluorouracil 58 ACC2 58 Bruton tyrosine kinase Btk 58 protein kinase inhibitor 58 Phosphatase 58 Uric Acid 58 Controlled Clinical Trial 58 adipogenic 58 Glycoprotein 58 G Protein Coupled 58 tyrosine kinase inhibitor 58 Survivin 58 Deforolimus 58 benzimidazole 58 microglial activation 58 vesicular monoamine transporter 58 Gleevec resistant 58 Protein Synthesis 58 Improves Survival 58 serine threonine 58 Synthetic Peptide 58 novel prodrug 58 Raltegravir 58 Endothelial Cells 58 Activating mutations 58 phosphate S1P 58 orally dosed 58 beta 1a 58 Plasmid DNA 58 murine monoclonal antibody 58 RNA Interference 58 ErbB3 58 novel VDA molecule 58 chemokine receptors 58 cyclooxygenase 58 Adjuvant Chemotherapy 58 NS4A 58 receptor modulators 58 Investigational Treatment 58 immune stimulatory 58 HSP# inhibitor 58 kinase inhibitors 58 antitumor 58 beta amyloid peptide 58 somatostatin analogue 58 Fludarabine 58 MicroRNA 58 Alkaline Phosphatase 58 IL 1ß 58 fusion protein 58 Bone Morphogenetic Protein 58 Luteinizing Hormone Releasing Hormone 58 plasmid encoding 58 inhibitory activity 58 TLR8 agonist 58 Molecular Mechanism 58 beta adrenergic 58 Virus Infection 57 histone deacetylases 57 Ganciclovir 57 nucleoside analogue 57 mTOR inhibitor 57 Polymorphism 57 Protein Kinase Inhibitors 57 Lung Cancer Drug 57 Fungal Infections 57 Allogeneic 57 serine protease 57 Xanafide 57 5 lipoxygenase 57 Adenoviral 57 Metastatic Melanoma 57 xenograft models 57 antibody MT# 57 Oncolytic Reovirus 57 PPARg 57 p# MAP kinase 57 TNFalpha 57 Tumour Necrosis Factor 57 triggers apoptosis 57 Hepatocyte 57 mediated inhibition 57 Humanized Anti 57 secretase 57 endothelin receptor 57 amikacin 57 Anticancer Drug 57 paclitaxel Taxol 57 Radiofrequency Ablation 57 aurora kinase 57 targeting CD# 57 metalloprotease 57 HER1 57 ara C 57 vascular disrupting agents 57 Enkephalin 57 small molecule Hedgehog 57 IGF1R 57 5 HT6 57 Trial Evaluating 57 Degarelix 57 1beta 57 TGF ß 57 antibody fragment 57 glucocorticoid receptor 57 Novel Therapeutic 57 peroxidase 57 potent topoisomerase II 57 gastrin 57 Microspheres 57 potently inhibits 57 Initiate Clinical Trial 57 5 HT2A receptor 57 Immunosuppression 57 geldanamycin 57 Hormone Refractory Prostate Cancer 57 tipifarnib 57 inflammatory PDE 57 Transdermal Patch 57 demethylating agent 57 ENMD # 57 PKC inhibitor 57 MMP2 57 Posiphen 57 Fibroblast Growth Factor Receptor 57 Chemotherapeutic Agents 57 Hypertensive Patients 57 Derived Factor 57 Drug Resistant 57 HepDirect prodrug 57 AMPA kainate 57 catenin 57 Soft Tissue Sarcoma 57 Elvitegravir 57 mecamylamine 57 anionic backbone 57 Metabolites 57 Combination Clinical Trial 57 regulated kinase ERK 57 Locked Nucleic Acid LNA 57 EGFr 57 HCV RNA polymerase 57 mitogen activated ERK kinase 57 elastase 57 Insulin Resistance 57 PAR1 57 mitotic kinesin 57 PPAR 57 highly selective endothelin 57 Allergic Rhinitis 57 drug zotarolimus 57 Ambrisentan 57 ERK pathway 57 agonist compounds 57 dihydrofolate reductase 57 Mutational 57 S1P 57 TLR2 57 topoisomerase 57 activating mutation 57 Dendritic Cell 57 multi kinase inhibitor 57 Tumor Growth 57 immunomodulating 57 Topoisomerase 57 uricase 57 cytostatic 57 Vidaza azacitidine 57 6 mercaptopurine 57 cholesteryl ester transfer 57 azoles 57 Darusentan 57 Estradiol 57 Phospholipid 57 PDE4 57 receptor monoclonal antibody 57 anticancer compound 57 Stromal 57 Restenosis 57 EGF receptor 57 androgen receptor AR 57 selectively inhibited 57 induce apoptosis 57 bifunctional 57 novel anticancer 57 Lentiviral 57 cyclooxygenase COX 57 E#F# 57 retinoic acid receptor 57 reuptake inhibitor 57 MTHFR 57 RANK Ligand 57 LY# [002] 57 vitro studies 57 Signaling Pathways 57 1α 57 NKG2D 57 Galectin 57 5alpha reductase 57 glycoprotein 57 apoptosis inducing 57 intravesical instillation 57 HDACs 57 Topoisomerase II 57 neurotrophic 57 Prospective Randomized 57 Drug Shows Promise 57 Clusterin 57 receptor CXCR4 57 avidin 57 microRNAs miR 57 Appears Safe 57 Refractory Hodgkin Lymphoma 57 monoclonal anti 57 Erythropoietic 57 immune modulator 57 potently inhibited 57 SGLT 57 glucagon receptor 57 PI3K/Akt 57 investigational compound 57 Effectively Treats 57 specific protein tyrosine 57 TNFa 56 Inhibitory 56 Significantly Reduces 56 prodrug 56 Archexin 56 Cutaneous T 56 Ziprasidone 56 REP# 56 oxidative stress inducer 56 Abeta peptide 56 Analogues 56 converting enzyme 56 Extracellular 56 bleomycin 56 Antithrombin 56 FAAH 56 CCX# 56 syngeneic 56 Lymphoid 56 Autoantibodies 56 selectively binds 56 intratumoral injection 56 HCV polymerase 56 meropenem 56 siRNA binds 56 dipeptidyl peptidase 4 56 acyltransferase 56 Breast Cancer Cells 56 EZN 56 sorafenib Nexavar 56 Patients Receiving 56 Cytotoxic T 56 Indomethacin 56 Mouse Models 56 selective adenosine 56 Renal Cell Carcinoma 56 Improves Outcomes 56 antitumoral 56 Inhibit 56 antiproliferative 56 monophosphate 56 thalidomide Thalomid 56 Topical Treatment 56 NR2B selective 56 Modulator 56 Monoamine Oxidase 56 Tyrosine 56 inhibitory effects 56 phosphoinositide 56 muscarinic 56 Increased Risk 56 Commence Phase 56 triciribine phosphate monohydrate 56 chemokine 56 NS5B polymerase 56 Fibroblast 56 Caveolin 1 56 Hepatocellular 56 Monoclonal Antibodies 56 prostanoid 56 Bevirimat 56 lipoxygenase 56 Adjunctive Therapy 56 Novel Method 56 NFkB 56 Cysteine 56 Tumor Cell 56 Chronic Sinusitis 56 FLT3 56 Malignant Glioma 56 mGluR2 NAM 56 Histone H3 56 MAPK 56 Modulating 56 KSP inhibitor 56 cyclooxygenase 2 56 reverse transcriptase inhibitor 56 prostaglandin synthesis 56 glycosyltransferase 56 MAP kinase 56 Somatostatin 56 chemically modified siRNA 56 receptor PPAR 56 Metabolic Disease 56 NK1 56 5' monophosphate 56 Diabetic Patients 56 Abl 56 CA4P 56 inverse agonist 56 chemotherapeutic agent 56 angiogenesis inhibitor 56 Antigen Specific 56 Previously Untreated 56 nicotinic acetylcholine receptor 56 Clinical Efficacy 56 neuroprotectant 56 Hypoxia Inducible Factor 56 gamma secretase inhibitors 56 IGF 1R 56 soluble tumor necrosis 56 Beneficial Effects 56 Antisense Drug 56 serotonin receptor 56 Analgesic 56 TLR7 56 Alfacell proprietary ribonuclease 56 diphosphate 56 partial agonist 56 Sirolimus Eluting Stent 56 non nucleoside 56 CYC# 56 protein tyrosine phosphatase 56 prostaglandin E2 PGE2 56 investigational oral 56 Aerosolized 56 Genes Involved 56 corticosteroid dexamethasone 56 topically administered 56 Maleate 56 serotonin reuptake inhibitor 56 tumor suppressor 56 generation purine nucleoside 56 agonist 56 pyrophosphate 56 anti secretory 56 superoxide dismutase 56 Unresectable 56 lysosomal 56 anti proliferative 56 potent antiproliferative 56 vinca alkaloid 56 kinase PI3K 56 JAK inhibitor 56 Tyrima 56 STAT3 56 Pivotal Study 56 Neurotransmitter 56 Imatinib mesylate 56 M1 muscarinic 56 Temsirolimus 56 Unfractionated Heparin 56 siRNA therapeutic 56 PC# cells 56 VAPRISOL 56 Vaccine Candidate 56 antifibrotic 56 D aspartic acid 56 VEGF pathway 56 FGFR 56 PKC isoforms 56 cytotoxic T lymphocyte 56 Î ² 56 cell adhesion molecule 56 delta isoform 56 polymerase inhibitors 56 CD# monoclonal antibody 56 SGLT 2 56 cytochrome P# 56 Statistically Significant 56 TNFα 56 2A receptor agonist 56 ligand TRAIL 56 Mesenchymal Stem Cells 56 Sevelamer 56 receptor modulator 56 Glufosfamide 56 oral dihydropyrimidine dehydrogenase DPD 56 Onconase 56 SOD1 56 Metastatic Renal Cell Carcinoma 56 tubulin binding 56 dose dependently 56 Sphingosine 1 56 PPARgamma 56 HMG CoA reductase inhibitors 56 Inflammatory Disease 56 vidofludimus 56 Amyloid 56 Oxidase 56 retaspimycin hydrochloride 56 immune modulatory 56 Respiratory Virus 56 HIF 1alpha 56 Mantle Cell Lymphoma 56 proto oncogene 56 CCR9 56 Randomized Phase II 56 Diffuse Large B 56 gefitinib Iressa 56 systemically administered 56 CTGF 56 Aurora kinase 56 MDM2 56 Adjuvant Treatment 56 HCV protease inhibitor 56 NMDA Receptor 56 glutamate receptors 56 TLR9 agonist 56 cyclin dependent kinases CDKs 56 Crizotinib 56 NF kappaB activation 56 NDA Submission 56 siRNA Delivery 56 COX Inhibiting Nitric Oxide 56 synthetic peptide 56 induced cytotoxicity 56 mGluR2 56 epothilones 56 5 HT2A serotonin 56 Targeted Therapies 56 PI3K pathway 56 negative allosteric modulator 56 oncogenic 56 Shows Efficacy 56 effector function 56 ZFP TF 56 dasatinib Sprycel 56 Polysaccharides 56 Fingolimod 56 imatinib resistant 56 c myc 56 Lymphocyte 56 Kinesin 56 CRAC channel 56 integrin alpha 56 SGLT2 inhibitor 55 immunotherapeutic 55 TGF beta1 55 alpha#beta# integrin 55 Shows Promise 55 factor Xa 55 adrenoceptor agonist 55 immunotoxin 55 mediated phosphorylation 55 aberrantly activated 55 INGN 55 TLR9 55 Oligomers 55 CD#L 55 Agonists 55 thymidylate synthase TS 55 histone deacetylase HDAC inhibitors 55 cytotoxic 55 5 HT3 receptor 55 factor receptor FGFR 55 cytochrome p# 55 TNF α 55 endothelin receptor antagonist 55 Breast Cancer Metastasis 55 Bicalutamide 55 protein phosphatase 55 PARP inhibitor 55 Aldosterone 55 neprilysin 55 Conjugates 55 nucleotide analog 55 immunoconjugate 55 M2 subunit 55 E selectin 55 JAK2 55 Regenerative Cells 55 EP1 receptor